Table 4.
Cost-effectiveness of PPIs for treatment of duodenal ulcer patients.
| Treatment strategy | Cost (US$) | Incremental cost (US$) | QALYs | Incremental QALYs | ICER |
|---|---|---|---|---|---|
| OME | 53023.30 | NA | 8077.61 | NA | NA |
| PAN | 126543.21 | 73519.91 | 8091.93 | 14.32 | 5134.67 |
| LAN | 304323.48 | 251300.18 | 8091.72 | 14.12 | 17801.67 |
| RAB | 430823.73 | 377800.43 | 8092.43 | 14.82 | 25488.31 |
| ILA | 1504703.48 | 1451680.18 | 8110.18 | 32.57 | 44572.22 |
QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio, Calculated as the average cost per patient and the average number of QALYs per patient in this strategy minus those of the treatment of OME; OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; NA, not applicable.